相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Mechanism of cis-Nerolidol-Induced Bladder Carcinoma Cell Death
Mateo Glumac et al.
CANCERS (2023)
Safety, efficacy, and pharmacokinetics of SH-1028 in EGFR T790M-positive advanced non-small cell lung cancer patients: A dose-escalation phase 1 study
Jing He et al.
CANCER (2023)
Design, synthesis, and biological evaluation of novel quinoline derivatives as small molecule mutant EGFR inhibitors targeting resistance in NSCLC: In vitro screening and ADME predictions
Ramakant A. Kardile et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2023)
Mapping of global, regional and national incidence, mortality and mortality-to-incidence ratio of lung cancer in 2020 and 2050
Rajesh Sharma
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2022)
Design, Synthesis, and Biological Evaluation of Novel EGFR PROTACs Targeting Del19/T790M/C797S Mutation
Hualin Zhang et al.
ACS MEDICINAL CHEMISTRY LETTERS (2022)
Chronicles of EGFR Tyrosine Kinase Inhibitors: Targeting EGFR C797S Containing Triple Mutations
Krishna Babu Duggirala et al.
BIOMOLECULES & THERAPEUTICS (2022)
Promising Role of Phytochemicals in the Prevention and Treatment of Cancer
Aziz Unnisa et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2022)
Consumption and cost trends of EGFR TKIs: influences of reimbursement and national price negotiation
Di Wu et al.
BMC HEALTH SERVICES RESEARCH (2022)
Emerging Approaches to Overcome Acquired Drug Resistance Obstacles to Osimertinib in Non-Small-Cell Lung Cancer
Matin Shaikh et al.
JOURNAL OF MEDICINAL CHEMISTRY (2022)
The Role of Extracellular Matrix Proteins in Breast Cancer
Arkadiusz Lepucki et al.
JOURNAL OF CLINICAL MEDICINE (2022)
Computational Prediction of Resistance Induced Alanine-Mutation in ATP Site of Epidermal Growth Factor Receptor
Tasia Amelia et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)
Overcoming C797S mutation: The challenges and prospects of the fourth-generation EGFR-TKIs
Hong-Yi Zhao et al.
BIOORGANIC CHEMISTRY (2022)
p38 alpha MAP kinase inhibitors to overcome EGFR tertiary C797S point mutation associated with osimertinib in non-small cell lung cancer (NSCLC): emergence of fourth-generation EGFR inhibitor
Iqrar Ahmad et al.
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS (2022)
Free energy perturbation guided Synthesis with Biological Evaluation of Substituted Quinoline derivatives as small molecule L858R/T790M/C797S mutant EGFR inhibitors targeting resistance in Non-Small Cell Lung Cancer (NSCLC)
Kshipra S. Karnik et al.
BIOORGANIC CHEMISTRY (2021)
Molecular Epidemiology of the Main Druggable Genetic Alterations in Non-Small Cell Lung Cancer
Sara S. Fois et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Beyond Osimertinib: The Development of Third-Generation EGFR Tyrosine Kinase Inhibitors For Advanced EGFR plus NSCLC
Misako Nagasaka et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Oral potentially malignant disorders: A consensus report from an international seminar on nomenclature and classification, convened by the WHO Collaborating Centre for Oral Cancer
Saman Warnakulasuriya et al.
ORAL DISEASES (2021)
Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer in Australia
Terence Khoo et al.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2021)
Lamellarin 14, a derivative of marine alkaloids, inhibits the T790M/C797S mutant epidermal growth factor receptor
Naoyuki Nishiya et al.
CANCER SCIENCE (2021)
Allosteric mutant-selective fourth-generation EGFR inhibitors as an efficient combination therapeutic in the treatment of non-small cell lung carcinoma
Surya Kant Tripathi et al.
DRUG DISCOVERY TODAY (2021)
Druggable Transient Pockets in Protein Kinases
Koji Umezawa et al.
MOLECULES (2021)
Resistance to Molecularly Targeted Therapies in Melanoma
Meet Patel et al.
CANCERS (2021)
Reframing recalcitrance for small-cell lung cancer
F. H. Blackhall
ANNALS OF ONCOLOGY (2021)
Comparison of first-generation EGFR-TKIs (gefitinib, erlotinib, and icotinib) as adjuvant therapy in resected NSCLC patients with sensitive EGFR mutations
Qihua He et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2021)
Therapeutic Targets In Breast Cancer Signaling: A Review
Emmanuel Ifeanyi Obeagu et al.
JOURNAL OF PHARMACEUTICAL RESEARCH INTERNATIONAL (2021)
Small cell lung cancer: a slightly less orphan disease after immunotherapy
J. Remon et al.
ANNALS OF ONCOLOGY (2021)
Design, synthesis and anticancer evaluation of new 4-anilinoquinoline-3-carbonitrile derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers
Min Zou et al.
BIOORGANIC CHEMISTRY (2021)
Cancer immunotherapy: A comprehensive appraisal of its modes of application
Mira Hoteit et al.
ONCOLOGY LETTERS (2021)
EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance
Mary Luz Uribe et al.
CANCERS (2021)
The Underappreciated Role of Epithelial Mesenchymal Transition in Chronic Obstructive Pulmonary Disease and Its Strong Link to Lung Cancer
Malik Quasir Mahmood et al.
BIOMOLECULES (2021)
Discovery of novel 9-heterocyclyl substituted 9H-purines as L858R/T790M/C797S mutant EGFR tyrosine kinase inhibitors
Hao Lei et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Insight into the Therapeutic Selectivity of the Irreversible EGFR Tyrosine Kinase Inhibitor Osimertinib through Enzyme Kinetic Studies
Xiang Zhai et al.
BIOCHEMISTRY (2020)
The significance of epidermal growth factor receptor uncommon mutations in non-small cell lung cancer: A systematic review and critical appraisal
Valerio Gristina et al.
CANCER TREATMENT REVIEWS (2020)
Design, synthesis and biological evaluation of potent EGFR kinase inhibitors against 19D/T790M/C797S mutation
Zhicheng Su et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2020)
A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy
Adileh Ayati et al.
BIOORGANIC CHEMISTRY (2020)
Efficacy and Safety of Epidermal Growth Factor Receptor (EGFR) Inhibitors Plus Antiangiogenic Agents as First-Line Treatments for Patients With AdvancedEGFR-Mutated Non-small Cell Lung Cancer: A Meta-Analysis
Fei Chen et al.
FRONTIERS IN ONCOLOGY (2020)
Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations
Oscar Arrieta et al.
BMC CANCER (2020)
CH7233163 Overcomes Osimertinib-Resistant EGFR-Del19/T790M/C797S Mutation
Kenji Kashima et al.
MOLECULAR CANCER THERAPEUTICS (2020)
Clinical development of targeted and immune based anti-cancer therapies
N. A. Seebacher et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Discovery of Potent and Noncovalent Reversible EGFR Kinase Inhibitors of EGFRL858R/T790M/C797S
Qiannan Li et al.
ACS MEDICINAL CHEMISTRY LETTERS (2019)
Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor
Ciric To et al.
CANCER DISCOVERY (2019)
Targeted protein degradation: elements of PROTAC design
Stacey-Lynn Paiva et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2019)
Structure-Based Design of 5-Methylpyrimidopyridone Derivatives as New Wild-Type Sparing Inhibitors of the Epidermal Growth Factor Receptor Triple Mutant (EGFRL858R/T790M/C797S)
Jiayi Shen et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Clinical management of third-generation EGFR inhibitor-resistant patients with advanced non-small cell lung cancer: Current status and future perspectives
Yi-Chen Zhang et al.
CANCER LETTERS (2019)
Optimizing outcomes and treatment sequences in EGFR mutation-positive non-small-cell lung cancer: recent updates
Nicolas Girard
FUTURE ONCOLOGY (2019)
The pharmacogenetics of natural products: A pharmacokinetic and pharmacodynamic perspective
Tai Rao et al.
PHARMACOLOGICAL RESEARCH (2019)
Start Selective and Rigidify: The Discovery Path toward a Next Generation of EGFR Tyrosine Kinase Inhibitors
Harald Engelhardt et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Lung Cancer in Mexico
Oscar Arrieta et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
EMT-Mediated Acquired EGFR-TKI Resistance in NSCLC: Mechanisms and Strategies
Xuan Zhu et al.
FRONTIERS IN ONCOLOGY (2019)
Role of osimertinib in the treatment of EGFR-mutation positive non-small-cell lung cancer
Jennifer W. Carlisle et al.
FUTURE ONCOLOGY (2019)
Structural insight into the binding mechanism of ATP to EGFR and L858R, and T790M and L858R/T790 mutants
Lucia Saldana-Rivera et al.
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS (2019)
Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy
Zuan-Fu Lim et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Elemene injection as adjunctive treatment to platinum-based chemotherapy in patients with stage III/IV non-small cell lung cancer: A meta-analysis following the PRISMA guidelines
Wang Xuewei et al.
PHYTOMEDICINE (2019)
Beyond EGFR inhibition: multilateral combat strategies to stop the progression of head and neck cancer
Hyung Kwon Byeon et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2019)
From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment (Review)
Volker Schirrmacher
INTERNATIONAL JOURNAL OF ONCOLOGY (2019)
Inhibition of osimertinib-resistant epidermal growth factor receptor EGFR-T790M/C797S
Jonas Lategahn et al.
CHEMICAL SCIENCE (2019)
Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer
C. Ricordel et al.
ANNALS OF ONCOLOGY (2018)
Targeting the C481S Ibrutinib-Resistance Mutation in Bruton's Tyrosine Kinase Using PROTAC-Mediated Degradation
Alexandru D. Buhimschi et al.
BIOCHEMISTRY (2018)
Synthesis and evaluation of 2,9-disubstituted 8-phenylthio/phenylsulfinyl-9H-purine as new EGFR inhibitors
Yuan-Yuan Hei et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2018)
In-silico evidences for binding of Glucokinase activators to EGFR C797S to overcome EGFR resistance obstacle with mutant-selective allosteric inhibition
Harun Patel et al.
COMPUTATIONAL BIOLOGY AND CHEMISTRY (2018)
Discovery of 2,4,6-trisubstitued pyrido[3,4-d]pyrimidine derivatives as new EGFR-TKIs
Hao Zhang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Dual or multi-targeting inhibitors: The next generation anticancer agents
Nulgumnalli Manjunathaiah Raghavendra et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Identification of small-molecule EGFR allosteric inhibitors by high-throughput docking
Fabiana Caporuscio et al.
FUTURE MEDICINAL CHEMISTRY (2018)
Design, Synthesis, and Structure-Activity Relationship Study of 2-Oxo-3,4-dihydropyrimido[4,5-d]pyrimidines as New Colony Stimulating Factor 1 Receptor (CSF1R) Kinase Inhibitors
Qiuju Xun et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Mechanisms of receptor tyrosine kinase activation in cancer
Zhenfang Du et al.
MOLECULAR CANCER (2018)
Allosteric Inhibitor TREA-0236 Containing Non-hydrolysable Quinazoline-4-one for EGFR T790M/C797S Mutants Inhibition
Seoyoung Lee et al.
BULLETIN OF THE KOREAN CHEMICAL SOCIETY (2018)
Real Clinical Practice of Using Afatinib Therapy in NSCLC Patients with an Acquired EGFR T790M Mutation
Kunihiko Miyazaki et al.
ANTICANCER RESEARCH (2018)
Osimertinib With Ramucirumab in EGFR-mutated, T790M-positive Patients With Progression During EGFR-TKI Therapy: Phase Ib Study
Hiroaki Akamatsu et al.
CLINICAL LUNG CANCER (2018)
Targeting EGFR(L858R/T790M) and EGFR(L858R/T790M/C797S) resistance mutations in NSCLC: Current developments in medicinal chemistry
Xiaoyun Lu et al.
MEDICINAL RESEARCH REVIEWS (2018)
Role of Epidermal Growth Factor Receptor (EGFR) and Its Ligands in Kidney Inflammation and Damage
Sandra Rayego-Mateos et al.
MEDIATORS OF INFLAMMATION (2018)
Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead
Daniel P. Bondeson et al.
CELL CHEMICAL BIOLOGY (2018)
Design, synthesis and evaluation of alkylphosphocholine-gefitinib conjugates as multitarget anticancer agents
Md. Maqusood Alam et al.
ARCHIVES OF PHARMACAL RESEARCH (2018)
Extracellular region of epidermal growth factor receptor: a potential target for anti-EGFR drug discovery
A. Dokala et al.
ONCOGENE (2017)
Trisubstituted Pyridinylimidazoles as Potent Inhibitors of the Clinically Resistant L858R/T790M/C797S EGFR Mutant: Targeting of Both Hydrophobic Regions and the Phosphate Binding Site
Marcel Gunther et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Lung Adenocarcinoma Harboring EGFR T790M and In Trans C797S Responds to Combination Therapy of First- and Third-Generation EGFR TKIs and Shifts Allelic Configuration at Resistance
Zhen Wang et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Most T790M mutations are present on the same EGFR allele as activating mutations in patients with non-small cell lung cancer
Noriko Hidaka et al.
LUNG CANCER (2017)
A Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of Pictilisib in Combination with Erlotinib in Patients with Advanced Solid Tumors
Stephen Leong et al.
ONCOLOGIST (2017)
The resistance mechanisms and treatment strategies for EGFR-mutant advanced non-small-cell lung cancer
Wen-Zhao Zhong et al.
ONCOTARGET (2017)
Novel quinoline-3-carboxamides (Part 2): Design, optimization and synthesis of quinoline based scaffold as EGFR inhibitors with potent anticancer activity
Rasha M. Aly et al.
BIOORGANIC CHEMISTRY (2017)
Design, synthesis and biological evaluation of WZ4002 analogues as EGFR inhibitors
Aireen A. Romu et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2017)
Recent Development of the Second and Third Generation Irreversible Epidermal Growth Factor Receptor Inhibitors
Weiwei Han et al.
CHEMISTRY & BIODIVERSITY (2017)
Discovery of EGF Receptor Inhibitors That Are Selective for the d746-750/T790M/C797S Mutant through Structure-Based de Novo Design
Hwangseo Park et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2017)
Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors
Takayuki Kosaka et al.
CANCER RESEARCH (2017)
Hybrid Compounds as Multitarget Directed Anticancer Agents
Ertan Kucuksayan et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2017)
EAI045: The fourth-generation EGFR inhibitor overcoming T790M and C797S resistance
Shuhang Wang et al.
CANCER LETTERS (2017)
Lung Cancer: EGFR Inhibitors with Low Nanomolar Activity against a Therapy-Resistant L858R/T790M/C797S Mutant
Marcel Guenther et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2016)
Recent progress on third generation covalent EGFR inhibitors
Hengmiao Cheng et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2016)
Discovery of a third-generation EGFR inhibitor, which is highly selective and potent against both resistant and activating EGFR mutations for NSCLC therapy
Rudi Bao et al.
CANCER RESEARCH (2016)
Development of the Third Generation EGFR Tyrosine Kinase Inhibitors for Anticancer Therapy
Weiyan Cheng et al.
CURRENT MEDICINAL CHEMISTRY (2016)
Challenges and Perspectives on the Development of Small-Molecule EGFR Inhibitors against T790M-Mediated Resistance in Non-Small-Cell Lung Cancer
Zhendong Song et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
4-Oxo-1,4-dihydroquinoline-3-carboxamide Derivatives as New Axl Kinase Inhibitors
Li Tan et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors
Yong Jia et al.
NATURE (2016)
Retrospective study of adjuvant icotinib in postoperative lung cancer patients harboring epidermal growth factor receptor mutations
Shuyang Yao et al.
THORACIC CANCER (2016)
EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients
D. Planchard et al.
ANNALS OF ONCOLOGY (2015)
The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies
Matthew J. Niederst et al.
CLINICAL CANCER RESEARCH (2015)
EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors
Dalia Ercan et al.
CLINICAL CANCER RESEARCH (2015)
Afatinib for the treatment of metastatic non-small cell lung cancer
Monika Joshi et al.
CANCER MANAGEMENT AND RESEARCH (2015)
Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial
Niki Karachaliou et al.
JAMA ONCOLOGY (2015)
Mechanisms of resistance to EGFR tyrosine kinase inhibitors
Lihua Huang et al.
ACTA PHARMACEUTICA SINICA B (2015)
A critical role for the long non-coding RNA GAS5 in proliferation and apoptosis in non-small-cell lung cancer
Xuefei Shi et al.
MOLECULAR CARCINOGENESIS (2015)
Acquired resistance to TKIs in solid tumours: learning from lung cancer
D. Ross Camidge et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2014)
Dermatological Side Effects of Epidermal Growth Factor Receptor Inhibitors: 'PRIDE' Complex
Bhushan Madke et al.
INDIAN JOURNAL OF DERMATOLOGY (2014)
Characteristics of Lung Cancers Harboring NRAS Mutations
Kadoaki Ohashi et al.
CLINICAL CANCER RESEARCH (2013)
Structure- and Reactivity-Based Development of Covalent Inhibitors of the Activating and Gatekeeper Mutant Forms of the Epidermal Growth Factor Receptor (EGFR)
Richard A. Ward et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Structural basis for the altered drug sensitivities of non-small cell lung cancer-associated mutants of human epidermal growth factor receptor
S. Yoshikawa et al.
ONCOGENE (2013)
Optimization of Substituted 6-Salicyl-4-Anilinoquinazoline Derivatives as Dual EGFR/HER2 Tyrosine Kinase Inhibitors
Dong-Dong Li et al.
PLOS ONE (2013)
Current role of EGF receptor monoclonal antibodies and tyrosine kinase inhibitors in the management of head and neck squamous cell carcinoma
Ana Markovic et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2012)
Design, Synthesis, and Biological Evaluation of Novel Conformationally Constrained Inhibitors Targeting Epidermal Growth Factor Receptor Threonine790 → Methionine790 Mutant
Shaohua Chang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
A Frozen Analogue Approach to Aminopyridinylimidazoles Leading to Novel and Promising p38 MAP Kinase Inhibitors
Roland Selig et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Effusion Immunocytochemistry as an Alternative Approach for the Selection of First-Line Targeted Therapy in Advanced Lung Adenocarcinoma
Tzu-Hsiu Tsai et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
Discovery of benzimidazole derivatives as novel multi-target EGFR, VEGFR-2 and PDGFR kinase inhibitors
Yunqi Li et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2011)
Managing treatment-related adverse events associated with egfr tyrosine kinase inhibitors in advanced non-small-cell lung cancer
V. Hirsh
Current Oncology (2011)
Treatment of Non-Small-Cell Lung Cancer with Erlotinib or Gefitinib
Vince D. Cataldo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Discovery of 7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDC-101) as a Potent Multi-Acting HDAC, EGFR, and HER2 Inhibitor for the Treatment of Cancer
Xiong Cai et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Novel Chimeric Histone Deacetylase Inhibitors: A Series of Lapatinib Hybrides as Potent Inhibitors of Epidermal Growth Factor Receptor (EGFR), Human Epidermal Growth Factor Receptor 2 (HER2), and Histone Deacetylase Activity
Siavosh Mahboobi et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Effect of gefitinib re-challenge to initial gefitinib responder with non-small cell lung cancer followed by chemotherapy
Yoshio Tomizawa et al.
LUNG CANCER (2010)
Targeted therapies in the treatment of advanced/metastatic NSCLC
A. G. Pallis et al.
EUROPEAN JOURNAL OF CANCER (2009)
Drug therapy: EGFR antagonists in cancer treatment
Fortunato Ciardiello et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Comparison of aspects of smoking among the four histological types of lung cancer
S. A. Kenfield et al.
TOBACCO CONTROL (2008)
Structures of lung cancer-derived EGFR mutants and inhibitor complexes: Mechanism of activation and insights into differential inhibitor sensitivity
Cai-Hong Yun et al.
CANCER CELL (2007)
Estimates of the cancer incidence and mortality in Europe in 2006
J. Ferlay et al.
ANNALS OF ONCOLOGY (2007)
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer
Scott Wilhelm et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Lapatinib: A novel EGFR/HER2 tyrosine kinase inhibitor for cancer
Stephen R. D. Johnston et al.
DRUGS OF TODAY (2006)
Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects
Carlo L. Bello et al.
ANTI-CANCER DRUGS (2006)
分享论文
